ArticleBlood2017
CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.
Article in Blood, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 29 citations in OpenAlex.
- Enhanced PIEZO1 expression in mast cells of mastocytosis skin lesions: Relevance to Darier's sign.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Article
- Diffuse Cutaneous Mastocytosis: A Current Understanding of a Rare Disease.International journal of molecular sciences · 2024Review
- The role and therapeutic targeting of the CCL2/CCR2 signaling axis in inflammatory and fibrotic diseases.Frontiers in immunology · 2024Review
- Current Challenges in the Diagnosis of Pediatric Cutaneous Mastocytosis.Diagnostics (Basel, Switzerland) · 2023Review
- Functionally Relevant Cytokine/Receptor Axes in Myelofibrosis.Biomedicines · 2023Review
- The Role of Mast Cells in the Induction and Maintenance of Inflammation in Selected Skin Diseases.International journal of molecular sciences · 2023Review
- CRISPR/Cas9-engineering of HMC-1.2 cells renders a human mast cell line with a single D816V-KIT mutation: An improved preclinical model for research on mastocytosis.Frontiers in immunology · 2023Article
- CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition inCancers · 2022Article
- -2518A/G polymorphism of monocyte chemotactic protein 1 (MCP-1/CCL2) is associated with cutaneous mastocytosis.Postepy dermatologii i alergologii · 2021Article
- Effects of Primary Mast Cell Disease on Hemostasis and Erythropoiesis.International journal of molecular sciences · 2021Review
- Mediator-Related Symptoms and Anaphylaxis in Children with Mastocytosis.International journal of molecular sciences · 2021Review
- Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.International journal of molecular sciences · 2021Review
- Genetic Regulation of Tryptase Production and Clinical Impact: Hereditary Alpha Tryptasemia, Mastocytosis and Beyond.International journal of molecular sciences · 2021Review
- Polyphenols and Cannabidiol Modulate Transcriptional Regulation of Th1/Th2 Inflammatory Genes Related to Canine Atopic Dermatitis.Frontiers in veterinary science · 2021Article
- Clinical features and survival of patients with indolent systemic mastocytosis defined by the updated WHO classification.Allergy · 2020Article
- International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study.The Lancet. Haematology · 2019Article
- Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?Expert review of clinical immunology · 2019Review
- Digital PCR: A Sensitive and Precise Method forClinical chemistry · 2018Article
- Expansion of BCR/ABL1British journal of haematology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 2 countries.
Funding
Abstract
Systemic mastocytosis (SM) is characterized by abnormal accumulation of neoplastic mast cells harboring the activating KIT mutation D816V in the bone marrow and other internal organs. As found in other myeloproliferative neoplasms, increased production of profibrogenic and angiogenic cytokines and related alterations of the bone marrow microenvironment are commonly found in SM. However, little is known about mechanisms and effector molecules triggering fibrosis and angiogenesis in SM. Here we show that KIT D816V promotes expression of the proangiogenic cytokine CCL2 in neoplastic mast cells. Correspondingly, the KIT-targeting drug midostaurin and RNA interference-mediated knockdown of KIT reduced expression of CCL2. We also found that nuclear factor κB contributes to KIT-dependent upregulation of CCL2 in mast cells. In addition, CCL2 secreted by KIT D816V
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.